Search Results - "Dijoseph, John F"

Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma by DIJOSEPH, John F, DOUGHER, Maureen M, KALYANDRUG, Lyka B, ARMELLINO, Douglas C, BOGHAERT, Erwin R, HAMANN, Philip R, MORAN, Justin K, DAMLE, Nitin K

“…Purpose: CMC-544 is a CD22-targeted cytotoxic immunoconjugate, currently being evaluated in B-cell non-Hodgkin's lymphoma (B-NHL) patients. Rituximab is a…”
Get full text

Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma by DIJOSEPH, John F, GOAD, Mary E, DOUGHER, Maureen M, BOGHAERT, Erwin R, KUNZ, Arthur, HAMANN, Philip R, DAMLE, Nitin K

“…Purpose: CMC-544 is a CD22-targeted immunoconjugate of calicheamicin and exerts a potent cytotoxic effect against CD22 + B-cell lymphoma. This study evaluated…”
Get full text

CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab by Dijoseph, John F, Dougher, Maureen M, Armellino, Douglas C, Kalyandrug, Lyka, Kunz, Arthur, Boghaert, Erwin R, Hamann, Philip R, Damle, Nitin K

“…Tumor-targeted delivery of a potent cytotoxic agent, calicheamicin, using its immunoconjugates is a clinically validated therapeutic strategy. Rituximab is a…”
Get full text

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 by DIJOSEPH, John F, POPPLEWELL, Andrew, ZINKEWICH-PEOTTI, Karen, STEPHENS, Sue, WEIR, Neil, DAMLE, Nitin K, TICKLE, Simon, LADYMAN, Heather, LAWSON, Alastair, KUNZ, Arthur, KHANDKE, Kiran, ARMELLINO, Douglas C, BOGHAERT, Erwin R, HAMANN, Philip R

“…Antibody-targeted chemotherapy with immunoconjugates of calicheamicin is a clinically validated strategy in cancer therapy. This study describes the selection…”
Get full text

Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells by DAMELIN, Marc, GELES, Kenneth G, BEHRENS, Carmen, CHOE, Sung E, RIOS, Carol, GRUZAS, Janet, SRIDHARAN, Latha, DOUGHER, Maureen, KUNZ, Arthur, HAMANN, Philip R, EVANS, Deborah, ARMELLINO, Douglas, FOLLETTIE, Maximillian T, KHANDKE, Kiran, MARQUETTE, Kimberly, TCHISTIAKOVA, Lioudmila, BOGHAERT, Erwin R, ABRAHAM, Robert T, WISTUBA, Ignacio I, ZHOU, Bin-Bing S, PING YUAN, BAXTER, Michelle, GOLAS, Jonathon, DIJOSEPH, John F, KARNOUB, Maha, SHUGUANG HUANG, DIESL, Veronica

“…Poorly differentiated tumors in non-small cell lung cancer (NSCLC) have been associated with shorter patient survival and shorter time to recurrence following…”
Get full text

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies by DiJoseph, John F., Armellino, Douglas C., Boghaert, Erwin R., Khandke, Kiran, Dougher, Maureen M., Sridharan, Latha, Kunz, Arthur, Hamann, Philip R., Gorovits, Boris, Udata, Chandrasekhar, Moran, Justin K., Popplewell, Andrew G., Stephens, Sue, Frost, Philip, Damle, Nitin K.

“…Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-γ-calicheamicin dimethyl hydrazide [CalichDMH],…”
Get full text

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP by DiJoseph, John F., Dougher, Maureen M., Evans, Deborah Y., Zhou, Bin-Bing, Damle, Nitin K.

“…Purpose CMC-544 (inotuzumab ozogamicin) is a CD22-specific immunoconjugate of calicheamicin currently being evaluated in patients with non-Hodgkin’s B-cell…”
Get full text

Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples by Boghaert, Erwin R., Khandke, Kiran M., Sridharan, Latha, Dougher, Maureen, DiJoseph, John F., Kunz, Arthur, Hamann, Philip R., Moran, Justin, Chaudhary, Inder, Damle, Nitin K.

“…Purpose The present study aims to establish a method that provides fast, precise and reproducible pharmacokinetic (PK) parameters of antibody-calicheamicin…”
Get full text

Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts by BOGHAERT, Erwin R, SRIDHARAN, Latha, FROST, Philip, DAMLE, Nitin K, ARMELLINO, Douglas C, KHANDKE, Kiran M, DIJOSEPH, John F, KUNZ, Arthur, DOUGHER, Maureen M, JIANG, Fan, KALYANDRUG, Lyka B, HAMANN, Philip R

“…Purpose: Linking a cytotoxic anticancer drug to an antibody that recognizes a tumor-associated antigen can improve the therapeutic index of the drug. We asked…”
Get full text

Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy by BOGHAERT, Erwin R, KHANDKE, Kiran, DISCAFANI, Carolyn, DAMLE, Nitin K, SRIDHARAN, Latha, ARMELLINO, Douglas, DOUGHER, Maureen, DIJOSEPH, John F, KUNZ, Arthur, HAMANN, Philip R, SRIDHARAN, Ashwin, JONES, Stanley

“…Calicheamicin is a potent chemotherapeutic with a low therapeutic index that requires targeting to tumor cells for its use in the clinic. To treat acute…”
Get full text

Synthesis and Structure−Activity Relationship of N-Substituted 4-Arylsulfonylpiperidine-4-hydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis by Aranapakam, Venkatesan, Davis, Jamie M, Grosu, George T, Baker, Ellingboe, John, Zask, Arie, Levin, Jeremy I, Sandanayaka, Vincent P, Du, Mila, Skotnicki, Jerauld S, DiJoseph, John F, Sung, Amy, Sharr, Michele A, Killar, Loran M, Walter, Thomas, Jin, Guixian, Cowling, Rebecca, Tillett, Jeff, Zhao, Weiguang, McDevitt, Joseph, Xu, Zhang Bao

“…The matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that play a key role in both physiological and pathological tissue…”
Get full text

Synthesis and Structure−Activity Relationship of α-Sulfonylhydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of Osteoarthritis by Aranapakam, Venkatesan, Grosu, George T, Davis, Jamie M, Hu, Baihua, Ellingboe, John, Baker, Jannie L, Skotnicki, Jerauld S, Zask, Arie, DiJoseph, John F, Sung, Amy, Sharr, Michele A, Killar, Loran M, Walter, Thomas, Jin, Guixian, Cowling, Rebecca

“…The matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that play a key role in both physiological and pathological tissue…”
Get full text

Synthesis and Structure−Activity Relationships of 4-alkynyloxy Phenyl Sulfanyl, Sulfinyl, and Sulfonyl Alkyl Hydroxamates as Tumor Necrosis Factor-α Converting Enzyme and Matrix Metalloproteinase Inhibitors by Venkatesan, Aranapakam M, Davis, Jamie M, Grosu, George T, Baker, Jannie, Zask, Arie, Levin, Jeremy I, Ellingboe, John, Skotnicki, Jerauld S, DiJoseph, John F, Sung, Amy, Jin, Guixian, Xu, Weixin, McCarthy, Diane Joseph, Barone, Dauphine

“…A series of 4-alkynyloxy phenyl sulfanyl, sulfinyl and sulfony alkyl and piperidine-4-carboxylic acid hydroxamides were synthesized. Their structure−activity…”
Get full text

Benzodiazepine inhibitors of the MMPs and TACE by NELSON, Frances C, DELOS SANTOS, Efren, GUIXIAN JIN, ROTH, Catherine E, ALBRIGHT, J. Donald, LEVIN, Jeremy I, CHEN, James M, SKOTNICKI, Jerauld S, DIJOSEPH, John F, SHARR, Michele A, SUNG, Amy, KILLAR, Loran M, COWLING, Rebecca

“…A series of benzodiazepine inhibitors of the MMPs and TACE has been developed. These compounds display an interesting selectivity profile and should be useful…”
Get full text

Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases by LEVIN, Jeremy I, YANSONG GU, COSMI, Scott, HSIAO, Chu-Lai, EDRIS, Wade, WILHELM, James, KILLAR, Loran M, SKOTNICKI, Jerauld S, NELSON, Frances C, ZASK, Arie, DIJOSEPH, John F, SHARR, Michele A, SUNG, Amy, GUIXIAN JIN, COWLING, Rebecca, CHANDA, Pranab

“…Heteroaryl and cycloalkyl sulfonamide-hydroxamic acid MMP inhibitors were investigated. Of these, the pyridyl analogue 2 is the most potent and selective…”
Get full text

The synthesis and biological activity of a novel series of diazepine MMP inhibitors by Levin, Jeremy I., DiJoseph, John F., Killar, Loran M., Sung, Amy, Walter, Thomas, Sharr, Michele A., Roth, Catherine E., Skotnicki, Jerauld S., Albright, J.Donald

“…A novel series of diazepine-based hydroxamic acid inhibitors of MMP-1, MMP-9, and MMP-13 were prepared and evaluated both in vitro and in vivo. A novel series…”
Get full text

THERAPEUTIC BLOOD LEVELS OF SIROLIMUS (RAPAMYCIN) IN THE ALLOGRAFTED RAT by DiJoseph, John F., Fluhler, Eric, Armsrong, Jay, Sharr, Michele, Sehgal, Suren N.

Get full text

N-Phenyl-2-pyridinecarbothioamides as gastric mucosal protectants by Kinney, William A, Lee, Nancy E, Blank, Robert M, Demerson, Christopher A, Sarnella, Carol S, Scherer, Noreen T, Mir, G. Nabi, Borella, Luis E, DiJoseph, John F, Wells, Cheryl

“…A series of substituted 2-pyridinecarbothioamides was synthesized and evaluated for gastric mucosal protectant activity in the rat. Out of this investigation…”
Get full text

Thrombocytopenia Induced by CMC-544 and Its Amelioration Using Oprelvekin (Neumega®/Recombinant Human Interleukin-11) by DiJoseph, John F., Walker, Dana, Dougher, Maureen M., Armellino, Doug C., Clarke, Dave, Damle, Nitin K.

“…CMC-544 is CD22-specific cytotoxic immunoconjugate of calicheamicin that has demonstrated significant anti-tumor activity in phase I clinical trial in B-NHL…”
Get full text

Antibody-Targeted Chemotherapy with Immunoconjugates of Calicheamicin: Differential Anti-Tumor Activity of Conjugated Calicheamicin Targeted to B-Cell Lymphoma Via B-Cell Lineage Specific Molecules CD19, CD20 and CD22 by DiJoseph, John F., Armellino, Douglas C., Dougher, Maureen M., Kunz, Arthur, Boghaert, Erwin R., Hamann, Philip R., Zinkewich-Peotti, Karen, Damle, Nitin K.

“…Antibody-targeted chemotherapy using tumor-targeted immunoconjugates of the cytotoxic agent, calicheamicin, is a clinically validated strategy for the…”
Get full text